What are the signs a healthcare technology company needs a Chief Revenue Officer?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Buying Committee in Healthcare Technology is a Multi-Head Hydra, Not a Decision-Making Unit

In healthcare technology, the buying committee is uniquely hostile to software purchasing because no single stakeholder can force a decision, yet any single stakeholder can kill a deal. The committee typically includes a clinical champion (often a department chair in radiology, pathology, or cardiology who wants the technology for their patients), a chief medical information officer (CMIO) who evaluates clinical workflow integration and data exchange with the EHR, a chief information security officer (CISO) who must approve any system that touches patient data, a chief financial officer (CFO) who demands a hard-dollar ROI calculation within 18 months, and a supply chain director who enforces GPO contract compliance. Each stakeholder evaluates the technology through a completely different lens: the clinical champion wants sensitivity and specificity data from peer-reviewed studies, the CMIO wants to see HL7 FHIR API documentation and integration timelines, the CISO wants a completed HITRUST CSF assessment or SOC 2 Type II report with no exceptions, the CFO wants a business case showing reduced readmission penalties or increased billing revenue, and the supply chain director wants the vendor to accept the GPO's pre-negotiated discount of 15-25% off list price. The deal size typically ranges from $150,000 to $1.5 million in annual recurring revenue for a multi-year agreement, but the shape is almost always a phased approach: a 60-90 day pilot at no cost or reduced cost (often $15,000-$40,000 to cover implementation and training), followed by a department-level rollout, then a health-system-wide expansion if the pilot metrics are met. Budget approval follows a rigid "capital request" process where the clinical champion must submit a formal business case to a capital allocation committee that meets monthly or quarterly, and the CFO has veto power over any request that does not show a payback period of less than 24 months. Deals stall most frequently at two specific points: first, when the pilot ends and the clinical champion must present results to a department-wide meeting where skeptical colleagues question whether the technology works on their specific patient population, not just the published study population; second, when the CISO's security review uncovers that the vendor's data encryption does not meet the health system's specific standards, which can require 4-8 weeks of remediation and re-review.

The Sales Cycle Forces a "Parallel Track" Motion That Breaks Traditional Funnel Management

The sales cycle in healthcare technology is not a sequential funnel but a parallel track system that most CRM implementations cannot model. Track one is the "clinical validation track" where the sales rep must build a relationship with the clinical champion, conduct multiple workflow observations to understand how the technology fits into existing clinical processes, design a pilot that the hospital's IRB may need to approve if patient data is involved, and then manage the pilot execution over 60-90 days. Track two is the "administrative procurement track" that runs simultaneously but independently, where the sales rep must complete a 100+ question security questionnaire, negotiate a business associate agreement (BAA) that satisfies both parties' legal teams, register the deal with the appropriate GPO to ensure the health system gets its contracted discount, and submit pricing that aligns with the health system's budget cycle. These two tracks are managed by different people in the health system who do not communicate with each other, meaning the sales rep must be a project manager who coordinates progress on both tracks without any internal advocate who can force alignment. The typical ramp time for a new sales rep is 12-15 months before they can independently manage both tracks on a single deal, and even then, the forecast is unreliable because the clinical validation track can complete successfully but the procurement track can stall for 6 months because the health system's legal team is backlogged or the capital allocation committee is not meeting due to a merger announcement. The pipeline shape is therefore "wide at the top with many pilots, narrow at the bottom with few contracts," and the leaks are not at the demo or proposal stage but at the "pilot completed but no procurement trigger" stage, where the clinical champion is satisfied but has no authority or process to initiate the procurement track. Without a CRO who understands that the sales motion is actually a clinical project management motion, the company will keep investing in pilots that produce clinical satisfaction but zero revenue.

The Pipeline Leaks Where the Revenue Team Has No "Deal Architect" Role

The most dangerous leak in a healthcare technology company is the absence of a "deal architect" who can bridge the clinical validation track and the procurement track. The sales team typically consists of former medical device reps who excel at building relationships with clinical champions and conducting product demonstrations, but they lack the project management skills to track security questionnaire progress, BAA negotiations, and GPO registration deadlines. The clinical implementation team consists of former clinicians who excel at training users and troubleshooting workflow issues, but they have no incentive to push the deal toward procurement because their compensation is tied to user satisfaction scores, not contract signatures. When a pilot completes successfully, the sales rep assumes the clinical champion will initiate the procurement process, but the clinical champion has no training in procurement and assumes the sales rep will handle it. The result is a 60-90 day dead zone where the pilot data sits in a folder, the clinical champion gets busy with patient care, and the sales rep moves on to the next pilot. Another leak is the "GPO discount negotiation" stage, where the sales rep agrees to a 20% discount without understanding that the health system's supply chain director will then demand an additional 10% "compliance discount" that the rep did not budget for, killing the deal's margin. Without a CRO who can create a "deal architect" role - a person who owns the procurement track for each deal while the sales rep owns the clinical track - the pipeline will leak revenue at every handoff between clinical validation and administrative procurement.

What a Revenue Leader Actually Looks Like in This Specific Context

A fractional or full-time CRO for a healthcare technology company must have a specific background that is surprisingly rare: they must have personally sold into health systems for at least 7 years, they must have managed both direct sales teams and clinical implementation teams, and they must have experience designing "pilot-to-procurement" playbooks that include specific clinical metrics as procurement triggers. The first 90 days are not about "building a sales process" or "implementing a CRM" - they are about auditing the existing deals and identifying which ones are stuck in the "pilot completed but no procurement initiated" dead zone. The CRO should spend weeks 1-4 conducting a "deal archaeology" exercise: for each of the 15-20 active pilots, they must interview the clinical champion to understand whether the pilot metrics were met, interview the sales rep to understand whether the security questionnaire and BAA have been started, and interview the health system's supply chain director to understand whether the deal is registered with the correct GPO. Weeks 5-8 should be spent redesigning the pilot agreement template so that it includes a "procurement initiation clause" - a specific clinical outcome (e.g., "reduce average report turnaround time by 30% for 200 consecutive cases") that, if met, automatically triggers a 30-day window for the health system to initiate the procurement process at a pre-negotiated price, or the vendor can walk away. Weeks 9-12 should be spent redesigning compensation: the clinical implementation team should have a "pilot-to-procurement transition bonus" worth 20% of their annual salary, paid only when a deal moves from pilot completion to signed contract within 90 days, and the sales team should have a "pilot completion quality score" that determines 25% of their commission, based on whether the pilot produced the data needed to trigger procurement. The operating cadence is not a weekly forecast call - it is a weekly "deal triage" meeting where the CRO reviews every deal that has completed a pilot in the last 60 days and asks: "Who is responsible for initiating the procurement track this week, and what is the specific action they will take?"

What the Revenue Leader Owns vs. Advises: The Hardest Boundary

In a healthcare technology company, the CRO must own the revenue function but advise on clinical evidence strategy and product roadmap - and this boundary is where most CROs fail because they either take on too much operational responsibility or stay too high-level. The CRO owns: the sales team (hiring, training, territory design, pipeline management, compensation), the clinical implementation team (capacity planning, incentive design, reporting structure, escalation management), the channel partner relationships (GPO contract negotiations, partner performance reviews, deal registration processes), and the pricing and packaging strategy (pilot pricing, enterprise pricing, GPO discount tiers, volume-based pricing). The CRO advises on: clinical study design (what endpoints the company's pilot studies should measure to convince procurement committees, not just clinical champions), product roadmap (which integration capabilities are most demanded by health system IT security teams, such as single sign-on or audit logging), and marketing content (white papers that speak to both the CFO's ROI requirements and the CISO's security requirements). The CRO does NOT own product development, clinical research, regulatory compliance, or customer success post-implementation - but they must be in the room when product roadmap decisions are made because a product that cannot pass a health system's security review or a pricing model that does not align with GPO reimbursement cycles will kill revenue regardless of sales effort. The signal to convert from fractional to full-time is when the company has at least three active deals simultaneously in the "procurement track" stage, meaning the security questionnaire is submitted, the BAA is under legal review, and the capital allocation committee has a meeting date scheduled - because that means the revenue architecture is producing pipeline velocity that now needs a full-time leader to scale, not just a fractional fixer who can design the system.

The First 90 Days: A Specific Playbook, Not Generic Advice

The first 90 days for a healthcare technology CRO must be structured around three deliverables that are unique to this industry's specific buying dynamics. Deliverable one (days 1-30): a "deal autopsy" of every active opportunity, categorized not by CRM stage but by which of the two tracks is blocked. The CRO should produce a heat map showing that, for example, 40% of deals have completed a successful pilot but have not initiated the procurement track because the clinical champion does not know how to start the process, 30% of deals have the procurement track started but are stalled at the security questionnaire because the vendor's security documentation is incomplete, 20% of deals are stalled at the GPO registration stage because the sales rep did not understand the health system's GPO affiliation, and 10% of deals are stalled because the clinical champion left the health system. This heat map drives the immediate action plan: create a "procurement initiation kit" that includes a pre-written business case template, a pre-completed security questionnaire, and a pre-negotiated GPO discount schedule that the clinical champion can submit directly to the capital allocation committee; hire a part-time security compliance specialist to complete outstanding security questionnaires within 2 weeks; and implement a "champion succession plan" where every clinical champion must identify a backup champion before the pilot begins. Deliverable two (days 31-60): a "pilot-to-procurement playbook" that includes a 12-week timeline with specific milestones for both tracks: week 1-2: clinical champion signs pilot agreement and identifies backup champion; week 3-4: sales rep submits security questionnaire and BAA to health system legal; week 5-8: pilot execution with weekly data reviews; week 9: pilot completion and data presentation to department head; week 10: clinical champion submits business case to capital allocation committee; week 11: procurement committee decision; week 12: contract signature. The playbook must include a "fail fast" trigger: if the security questionnaire has not been submitted by week 4 or the pilot data does not meet the pre-defined clinical metric by week 8, the deal is moved to "nurture" status and the sales rep stops active investment. Deliverable three (days 61-90): a channel partner scorecard that evaluates each GPO or distributor partner on three metrics: number of health system introductions made in the last 6 months, number of pilots started from those introductions, and number of pilots converted to enterprise deals. Any partner that has not produced a pilot conversion in 12 months is put on a 90-day performance improvement plan or terminated. This 90-day playbook is not about "building a sales culture" or "implementing a CRM" - it is about creating a repeatable clinical-to-procurement machine that the CEO can trust to produce predictable revenue from a pipeline that previously produced only activity.

FAQ

What specific revenue stagnation patterns indicate a CRO is needed? When a healthcare technology company sees flat or declining revenue despite strong product-market fit, increased marketing spend, and a growing sales headcount, it often signals a coordination failure. A CRO can unify sales, marketing, and customer success around a single revenue engine, eliminating the friction between departments that causes leakage.

How does misalignment between clinical sales and technical sales cycles signal the need for a CRO? Healthcare technology sales often involve long, multi-stakeholder cycles where clinical buyers (physicians, nurses) and economic buyers (hospital administrators, CFOs) have different timelines and priorities. When sales teams cannot consistently manage these parallel tracks, a CRO can design a structured, repeatable process that addresses both value propositions without losing momentum.

What role does customer churn play in the decision to hire a CRO? High or unpredictable churn, especially after a large implementation investment, often indicates that the handoff from sales to customer success is broken. A CRO can own the entire post-sale journey, ensuring that contracted value translates into realized clinical and operational outcomes, which directly reduces churn and expands contract value.

When does a founder-CEO's dual role as chief sales officer become a liability? When a founder can no longer personally close every deal, or when their presence becomes a bottleneck for scaling the sales process, it is a clear sign. A CRO brings the operational discipline to build a scalable sales infrastructure, freeing the founder to focus on product vision and strategic partnerships without leaving revenue growth to chance.

Sources